BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 28467815)

  • 1. Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A.
    Szarc Vel Szic K; Declerck K; Crans RAJ; Diddens J; Scherf DB; Gerhäuser C; Vanden Berghe W
    Oncotarget; 2017 Jun; 8(25):40434-40453. PubMed ID: 28467815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological levels of Withaferin A (Withania somnifera) trigger clinically relevant anticancer effects specific to triple negative breast cancer cells.
    Szarc vel Szic K; Op de Beeck K; Ratman D; Wouters A; Beck IM; Declerck K; Heyninck K; Fransen E; Bracke M; De Bosscher K; Lardon F; Van Camp G; Vanden Berghe W
    PLoS One; 2014; 9(2):e87850. PubMed ID: 24498382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells.
    Das SG; Romagnoli M; Mineva ND; Barillé-Nion S; Jézéquel P; Campone M; Sonenshein GE
    Breast Cancer Res; 2016 Apr; 18(1):40. PubMed ID: 27039296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different effects of 4β-hydroxywithanolide E and withaferin A, two withanolides from Solanaceae plants, on the Akt signaling pathway in human breast cancer cells.
    Wang HC; Hu HH; Chang FR; Tsai JY; Kuo CY; Wu YC; Wu CC
    Phytomedicine; 2019 Feb; 53():213-222. PubMed ID: 30668401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of BRMS1 by DNA hypermethylation and its association with metastatic progression in triple-negative breast cancer.
    Kong B; Lv ZD; Wang Y; Jin LY; Ding L; Yang ZC
    Int J Clin Exp Pathol; 2015; 8(9):11076-83. PubMed ID: 26617826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines.
    de Oliveira SF; Ganzinelli M; Chilà R; Serino L; Maciel ME; Urban Cde A; de Lima RS; Cavalli IJ; Generali D; Broggini M; Damia G; Ribeiro EM
    PLoS One; 2016; 11(1):e0145647. PubMed ID: 26751376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
    Kozomara Z; Supic G; Krivokuca A; Magic Z; Dzodic R; Milovanovic Z; Brankovic-Magic M
    J BUON; 2018; 23(3):684-691. PubMed ID: 30003738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
    Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
    Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.
    Roll JD; Rivenbark AG; Sandhu R; Parker JS; Jones WD; Carey LA; Livasy CA; Coleman WB
    Exp Mol Pathol; 2013 Dec; 95(3):276-87. PubMed ID: 24045095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased hypermethylation of glutathione S-transferase P1, DNA-binding protein inhibitor, death associated protein kinase and paired box protein-5 genes in triple-negative breast cancer Saudi females.
    Hafez MM; Al-Shabanah OA; Al-Rejaie SS; Al-Harbi NO; Hassan ZK; Alsheikh A; Al Theyab AI; Aldelemy ML; Sayed-Ahmed MM
    Asian Pac J Cancer Prev; 2015; 16(2):541-9. PubMed ID: 25684485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Withaferin A inhibits in vivo growth of breast cancer cells accelerated by Notch2 knockdown.
    Kim SH; Hahm ER; Arlotti JA; Samanta SK; Moura MB; Thorne SH; Shuai Y; Anderson CJ; White AG; Lokshin A; Lee J; Singh SV
    Breast Cancer Res Treat; 2016 May; 157(1):41-54. PubMed ID: 27097807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.
    Ward AK; Mellor P; Smith SE; Kendall S; Just NA; Vizeacoumar FS; Sarker S; Phillips Z; Alvi R; Saxena A; Vizeacoumar FJ; Carlsen SA; Anderson DH
    Breast Cancer Res; 2016 Jan; 18(1):12. PubMed ID: 26810754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
    Toffoli S; Bar I; Abdel-Sater F; Delrée P; Hilbert P; Cavallin F; Moreau F; Van Criekinge W; Lacroix-Triki M; Campone M; Martin AL; Roché H; Machiels JP; Carrasco J; Canon JL
    Breast Cancer Res; 2014 Nov; 16(6):466. PubMed ID: 25416589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
    Yam C; Mani SA; Moulder SL
    Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down regulation of ADAM33 as a Predictive Biomarker of Aggressive Breast Cancer.
    Manica GC; Ribeiro CF; Oliveira MA; Pereira IT; Chequin A; Ramos EA; Klassen LM; Sebastião AP; Alvarenga LM; Zanata SM; Noronha L; Rabinovich I; Costa FF; Souza EM; Klassen G
    Sci Rep; 2017 Mar; 7():44414. PubMed ID: 28294120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenomic Profiling Advises Therapeutic Potential of Leukotriene Receptor Inhibitors for a Subset of Triple-Negative Breast Tumors.
    Kalinkin AI; Sigin VO; Kuznetsova EB; Ignatova EO; Vinogradov II; Vinogradov MI; Vinogradov IY; Zaletaev DV; Nemtsova MV; Kutsev SI; Tanas AS; Strelnikov VV
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple-negative breast cancer molecular subtyping and treatment progress.
    Yin L; Duan JJ; Bian XW; Yu SC
    Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Application of Non-Invasive Apoptosis Detection Sensor (NIADS) on Histone Deacetylation Inhibitor (HDACi)-Induced Breast Cancer Cell Death.
    Hsu KW; Huang CY; Tam KW; Lin CY; Huang LC; Lin CL; Hsieh WS; Chi WM; Chang YJ; Wei PL; Chen ST; Lee CH
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translational Epidemiology: An Integrative Approach to Determine the Interplay Between Genetic Ancestry and Neighborhood Socioeconomic Status on Triple Negative Breast Cancer.
    Goel N; Yadegarynia S; Kwon D; Kesmodel SB; Harbour JW; Kobetz E; Merchant N; Rodriguez DA
    Ann Surg; 2022 Sep; 276(3):430-440. PubMed ID: 35758508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.